High priorities: sustainability & continual improvement LEARN MORE>
High priorities: sustainability & continual improvement
Actavis Completes Forest Laboratories Acquisition LEARN MORE>
Actavis Completes Forest Laboratories Acquisition
>Go!

Specialty R&D

Strengthening Our Premier Brands Pipeline

Actavis brands R&D team drives an industry-leading pipeline of product opportunities focused on ensuring sustainable growth in key therapeutic categories including Dermatology and Aesthetics; Eye Care; CNS; Women’s Health and Urology; Anti-infectives and Gastroenterology.

Strengthened by our acquisition of Allergan in March 2015, the pipeline features more than 20 innovative products in near- or mid-term development, including Cariprazine, Eluxadoline, Esmya, Aczone X and Darpin AMD.

Our R&D strategy is focused on continuing to build this pipeline through organic development as well as partnerships, collaborations and in-licensing.